Search

With the increase of antibiotic use, certain bacterial strains evolved developing resistance to the drugs to which they were initially sensitive. The fight against antimicrobial resistance is based on an ethical principle for the protection of human, animal and environmental health. In this paper, we aim to provide an overview on the ethical challenges that arise in the context of antimicrobial resistance. Who should have access to antibiotics? Who should get antibiotics? Should current use of antibiotics be restricted? These are just some of the ethical questions that need to be addressed. A report of the World Health Organization (WHO) shows that drug resistance - particularly antibiotic resistance - is a growing threat to human health, food security and modern medicine. When people recklessly use antibiotics to fight a common cold, when farmers use antibiotics to boost animal productivity, the bacteria that the drugs are designed to kill become immune. Unfortunately, this is a scary reality. In conclusion, antimicrobial resistance has been described as one of the main threats to individual health and population in the 21st century, and national and international organizations have repeatedly emphasized the urgent need for action.

Introduction: Henoch-Schonlein purpura (HSP), is a self-limiting vasculitis involving the small vessels of the skin, gastrointestinal tract, kidneys, joints, and rarely the lungs and central nervous system (CNS). The severe acute respiratory syndrome coronavirus-2 (Sars-CoV-2) infection may be a condition associated with the development of vasculitis sustained by an exacerbated IgA-mediated immune response. Case Description/Methods: In the context of the current pandemic, we report the case of a 32-yearold patient who showed clinical features of HSP that appeared in a few days after the diagnosis of Coronavirus Disease 2019 (COVID-19) mild form, confirmed by PCR test. He presented an acute onset with marked asthenia, edema and painful bilateral swelling of the knee, associated with difficulty walking. Small flat lesions distributed on the upper and lower extremity and on the posteriorchest have been identified, one day later. He needed hospitalization in a medical center where he received corticosteroid therapy, anticoagulant, antiviral with regression of skin lesions and joint swelling. After five days the skin lesions expand and after 48 hours there is intense abdominal pain accompanied by accelerated intestinal transit with blood. The objective examination reveals a rash on both lower extremity, which extends from the soles to the ankles (Figure 1). Examination of the knee joints shows no local erythema, but a painful limitation of passive movements is noted. Laboratory data indicate a biological inflammatory syndrome, proteinuria and hematuria. The immunological profile does not indicate the presence of non-COVID-19 reactive arthritis. Upper gastrointestinal examination performed at 4 days reveals gastric vascular spots. There are no evidence of suggestive lesions for inflammatory bowel disease (IBD) observed both on colonoscopy and abdominal CT based on 7 mm parietal thickening of the descending colon and sigmoid. Clinical, laboratory, imaging and endoscopic data establish the diagnosis of HSP with nephritic syndrome and reactive arthritis in the context of Sars-CoV-2 infection. Under cortisone treatment, purpura disappears completely after 10 days. Discussion: In our patient the presence of purpura in the absence of thrombocytopenia, as a mandatory criterion, in association with other criteria, namely arthritis reactive at onset, renal and digestive impairment, support according to EULAR / PRINTO / PRES criteria, the diagnosis of Henoch-Schonlein purpura..